Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $50.93 and traded as high as $64.61. Global X Genomics & Biotechnology ETF shares last traded at $64.26, with a volume of 52,712 shares trading hands.

Global X Genomics & Biotechnology ETF Trading Down 1.1%

The business has a fifty day moving average of $58.96 and a 200-day moving average of $50.93. The firm has a market cap of $93.82 million, a PE ratio of -27.46 and a beta of 1.19.

Global X Genomics & Biotechnology ETF Dividend Announcement

The company also recently disclosed a semiannual dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were given a $0.0579 dividend. This represents a dividend yield of 20.0%. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is -27.35%.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after purchasing an additional 10,308 shares during the period. Sei Investments Co. increased its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after purchasing an additional 4,615 shares during the period. Creative Financial Designs Inc. ADV raised its position in shares of Global X Genomics & Biotechnology ETF by 4.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after buying an additional 481 shares in the last quarter. Finally, Wealth Management Partners LLC purchased a new stake in shares of Global X Genomics & Biotechnology ETF in the first quarter worth $244,000. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.